Feature | February 10, 2014

Interventional Cardiologist Redefines Value for Everyday Medical Practice

February 10, 2014 — Achieving real quality improvement and reducing costs means re-evaluating what constitutes value, according to a new paper e-published in the journal Catheterization and Cardiovascular Interventions (CCI). A new formula to define value, as presented in the paper, equates “real value” with appropriateness together with clinically defined outcomes and patient-expected outcomes relative to costs.
 
“Physicians are ready for new tools and strategies to improve patient care, and interventional cardiologists’ long-standing commitment to innovation and quality improvement have enabled us to propose a solution and kick-start its adoption,” said Peter L. Duffy, M.D., MMM, FSCAI, medical director of the cardiovascular service line at the Reid Heart Center/FirstHealth of the Carolinas, Pinehurst, N.C., and the paper’s author.
 
The Real Value Equation captures the Institute of Medicine’s (IOM) six dimensions of quality: care that is safe, effective, efficient, timely, patient-centered and equitable. It emphasizes how its application will help physicians provide better care by allowing them to customize care for individual patient’s needs while adhering to best practices, guidelines and appropriate use criteria (AUC). The lens through which interventional cardiologists can view decisions is based on the following four parameters:
 
The extent to which the benefit of the procedure outweighs the risk
The expected effect on the patient’s quality of life
How much the procedure reduces long- and short-term risk of complications
Whether the procedure will extend the patient’s life expectancy with the level of quality of life they expect
 
The author said focusing on AUC alone will not result in better population-based outcomes and will not address long-standing concerns regarding patient-centered care and spiraling healthcare costs, however. He called for interventional cardiologists to integrate appropriateness with clinical outcomes, patient expectations and resource utilization into clinical practice. 
 
“With heart disease care accounting for more than 40 percent of every healthcare dollar spent in the United States, interventional cardiologists are at the forefront of the conversation about how to change health care,” Duffy said. “We have the ability to make changes in our practice that will lead the way to meaningful change in this new phase of healthcare reform. As the Real Value equation takes hold, the possibilities to apply it beyond cardiology to every field will only become clearer, which is truly exciting.”
 
The paper is titled “Real Value: A Strategy for Interventional Cardiologists to Lead Healthcare Reform.” 
 
For more information: www.SCAI.org

Related Content

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Diamondback 360 Peripheral OAS image courtesy of Cardiovascular Systems Inc.

Technology | Atherectomy Devices| July 22, 2015
Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
cardiac rehab after angioplasty, rehabilitation, ACC, Randal J. Thomas, referral
Feature | Cardiac Rehabilitation| July 17, 2015
Hospitals in the Midwest were more likely than others to refer patients for guideline-recommended cardiac...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Medtronic, Protege GPS self-expanding peripheral stent, FDA approval
Technology | July 16, 2015
Medtronic plc announced that its Protege GPS self-expanding peripheral stent system has received approval from the U.S...
Overlay Init